Asco-GU 2019 – checkpoint blockers might not be created equal after all
Asco-GU 2019 – checkpoint blockers might not be created equal after all
Marketing Between Merck and Pfizer, the race is on in kidney cancer—but analysts are calling it early
Marketing
Between Merck and Pfizer, the race is on in kidney cancer—but analysts are calling it early
Big Keytruda survival win sets Merck up to steal Bristol-Myers Squibb’s kidney cancer share
Big Keytruda survival win sets Merck up to steal Bristol-Myers Squibb’s kidney cancer share
Upcoming events – Cancer readouts for Merck & Co and Seattle
Upcoming events – Cancer readouts for Merck & Co and Seattle
Regeneron’s Libtayo is chugging along in skin cancer. Next stop? First-line lung
Regeneron’s Libtayo is chugging along in skin cancer. Next stop? First-line lung
The Top 6 Companies of the Pharmaceutical Innovation Index 2018
The Top 6 Companies of the Pharmaceutical Innovation Index 2018
The skeptics were right: Bristol-Myers has pulled a crucial Opdivo lung filing as it awaits more data
The skeptics were right: Bristol-Myers has pulled a crucial Opdivo lung filing as it awaits more data
Look out for a Q4 surprise from BMS’ Opdivo, but Merck’s Keytruda will stay on top: analyst
Look out for a Q4 surprise from BMS’ Opdivo, but Merck’s Keytruda will stay on top: analyst
The Celgene Legacy: Innovative Science and Price Gouging
The Celgene Legacy: Innovative Science and Price Gouging
Lilly suspends Lartruvo promotion after Phase 3 failure
Κάντε like στη σελίδα μας στο facebook για να μαθαίνετε πρώτοι όλα τα νέα!! Dive Brief: Eli Lilly’s Lartruvo failed a Phase 3 study in advanced or metastatic soft … Continue Reading Lilly suspends Lartruvo promotion after Phase 3 failure
Νέα θεραπεία για νεφροκυτταρικό καρκίνωμα
Νέα θεραπεία για νεφροκυτταρικό καρκίνωμα
AstraZeneca mines for positives in Imfinzi’s failed Mystic lung cancer trial
AstraZeneca mines for positives in Imfinzi’s failed Mystic lung cancer trial
Can Bristol-Myers’ latest Opdivo results preserve its small-cell lung cancer nod?
Can Bristol-Myers’ latest Opdivo results preserve its small-cell lung cancer nod?
Roche wins key cancer drug approval, but taking on Merck remains a challenge
Roche wins key cancer drug approval, but taking on Merck remains a challenge
Roche’s Tecentriq gets first-line lung cancer approval
Roche’s Tecentriq gets first-line lung cancer approval
Roche’s Tecentriq wins key lung cancer approval. Its prize? A showdown with formidable Merck
Roche’s Tecentriq wins key lung cancer approval. Its prize? A showdown with formidable Merck
